Compare iShares MSCI South Africa ETF (EZA) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Africa ETF vs Zoetis Inc — how do they compare? iShares MSCI South Africa ETF trades at $68.53, while Zoetis Inc trades at $73.44 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while iShares MSCI South Africa ETF pays none, and iShares MSCI South Africa ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| EZA | ZTS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $81.60 | $156.76 |
52-Week Low | $56.57 | $71.91 |
Market Cap | — | $31.14B |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EZA trades at $68.43, down 1.86% with technical indicators showing mixed signals. The stock maintains bullish moving averages but faces overbought conditions with RSI readings above 70. Recent dividend declaration of $1.43 for H1-2026 provides income appeal, though fundamental metrics remain undisclosed in current data.
South African market exposure presents both opportunity and risk given current macroeconomic pressures on financials and commodities. The ETF's heavy weighting in gold, banking, and platinum group metals faces headwinds from global reflation trends, requiring careful monitoring of constituent performance.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI South Africa ETF
EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
